Preclinical Fragile X Syndrome Studies
Fragile X syndrome is a genetic disorder caused by a CGG expansion in the FMR1 gene. This condition tends to...
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer
PARAMUS, N.J., November 4, 2019 – PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer...
News
Stay up to date on PsychoGenics and the world of preclinical drug discovery.
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of...
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Oct 11, 2022 · Business Wire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and...
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997 is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using PsychoGenics’ AI-enabled phenotypic screening platforms. PsychoGenics intends to evaluate RO7117997 as a potential treatment for several psychiatric and neurological conditions, starting with sleep and seizure disorders.
Preclinical In Vivo Electrophysiology Services
Single-Unit, Multi-Unit, and Local Field Potential Recording Preclinical in vivo electrophysiology services utilizing fully intact models deliver a powerful advantage...
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
Daniela Brunner, Chief Innovation Officer; Geoffrey Varty, Executive Vice President, Research Operations; and Leslie Street, Vice President, Medicinal Chemistry PsychoGenics Inc....
Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity
Udyavar A R, Wooten D J, Hoeksema M, Bansal M, Califano A, Estrada L, Schnell S, Irish J M, Massion...
Drug Abuse Liability Services
PsychoGenics has been a leader in the field of drug abuse liability for over a decade, specializing in the validation...